Not finding it? Sign in to also search OpenAlex live.
-
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study2020 British Journal of Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access
Hans A. J. Gelderblom, Robin L. Jones, Suzanne George, Claudia Valverde Morales, Charlotte Benson, Jean‐Yves Blay, +8 more
24citations -
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial2025 British Journal of Cancer article Medicine Gastrointestinal Tumor Research and Treatment Open access
Desmond Yip, John Raymond Zalcberg, Jean‐Yves Blay, David Espinoza, Timothy Jay Price, Sandrine I. Marreaud, +8 more
4citations -
Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
Mahmoud Mohammadi, Thekla M. Werkhoven, Nikki S. IJzerman, Dide den Hollander, Roos F. Bleckman, Astrid W. Oosten, +4 more
5citations -
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study2021 Clinical Cancer Research article Medicine Gastrointestinal Tumor Research and Treatment Open access
Bruno Vincenzi, Andrea Napolitano, Marta F. Fiocco, Olivier Mir, Piotr Lukasz Rutkowski, Jean‐Yves Blay, +31 more
47citations -
Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.2024 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
John Raymond Zalcberg, Robin L. Jones, Jean‐Yves Blay, Suzanne George, Hans A. J. Gelderblom, Patrick Schöffski, +12 more
2citations -
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial2022 Journal of Clinical Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access
Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay, Hans A. J. Gelderblom, Suzanne George, Patrick Schöffski, +13 more
121citations -
Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series2024 Current Problems in Cancer Case Reports article Medicine Gastrointestinal Tumor Research and Treatment Open access
Deborah van de Wal, Evelyne Roets, Roos F. Bleckman, Jorn Nützinger, Birthe C. Heeres, Jan Martijn Kerst, +6 more
1citations -
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial2021 The Lancet Respiratory Medicine article Medicine COVID-19 Clinical Research Studies Open access
Jurjan Aman, Erik Duijvelaar, Liza Botros, Azar Kianzad, Job R. Schippers, Patrick J. Smeele, +58 more
125citations -
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib
Alessandro Gronchi, Sylvie Bonvalot, Andrés Poveda Velasco, Dusan Kotasek, Piotr Lukasz Rutkowski, Peter Hohenberger, +18 more
96citations -
INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib2022 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
Michael Charles Heinrich, Robin L. Jones, Hans A. J. Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, +13 more
18citations -
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
Maria Abbondanza Pantaleo, Michael Charles Heinrich, Antoîne Italiano, Claudia María Valverde, Patrick Schöffski, Giovanni Grignani, +8 more
11citations -
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.
Michael Charles Heinrich, Jean‐Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, +7 more
1citations -
Feasibility and clinical outcomes of imatinib personalized dosing in gastrointestinal stromal tumor patients.2025 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
Maud B. A. van der Kleij, Eline L. Giraud, Niels A.D. Guchelaar, Kim Westerdijk, Marinda Meertens, Roos F. Bleckman, +12 more
1citations -
Assessing Safety of the Transition to Generic Imatinib in Patients with Gastrointestinal Stromal Tumours2025 Oncology and Therapy article Medicine Gastrointestinal Tumor Research and Treatment Open access
Joris M. van Sabben, Maud B. A. van der Kleij, Evelyne Roets, Renaud Tissier, Dorieke E M van Balen, Alwin D. R. Huitema, +4 more
0citations -
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Kateřina Machová Poláková, Ali Albeer, Václava Polívková, Monika Krutska, Katerina Vlcanova, Nikola Čuřík, +30 more
7citations -
Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.2023 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
Sebastian Bauer, Robin L. Jones, Suzanne George, Hans A. J. Gelderblom, Patrick Schöffski, Margaret von Mehren, +13 more
16citations